Ligand Pharmaceuticals Launches Pelthos to Accelerate Commercialization of Zelsuvmi for Molluscum; Appoints New CEO
Ligand Pharmaceuticals is launching Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and has appointed Scott Plesha as Chief Executive Officer to accelerate the commercialization of berdazimer topical gel, 10.3% (Zelsuvmi) for the treatment of molluscum contagiosum. Prior to joining Pelthos, Mr. Plesha was President and Chief Commercial Officer at BioDelivery Sciences (BDSI) until it was acquired […]